KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Equity Ratio (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Equity Ratio for 16 consecutive years, with 0.21 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 16.14% to 0.21 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.21, a 16.14% increase, with the full-year FY2025 number at 0.21, up 16.14% from a year prior.
  • Equity Ratio was 0.21 for Q4 2025 at Bristol Myers Squibb, up from 0.0 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.46 in Q3 2022 to a low of 0.4 in Q4 2022.
  • A 4-year average of 0.06 and a median of 0.09 in 2024 define the central range for Equity Ratio.
  • Biggest YoY gain for Equity Ratio was 71405.53% in 2022; the steepest drop was 3338.6% in 2022.
  • Bristol Myers Squibb's Equity Ratio stood at 0.01 in 2021, then crashed by 3338.6% to 0.4 in 2022, then soared by 144.37% to 0.18 in 2024, then rose by 16.14% to 0.21 in 2025.
  • Per Business Quant, the three most recent readings for BMY's Equity Ratio are 0.21 (Q4 2025), 0.0 (Q1 2025), and 0.18 (Q4 2024).